Chimeric Therapeutics Limited (ASX:CHM) Financings

Chimeric Therapeutics Limited

Financings

RaiseDateIn US dollars
Convertible notes with associated warrants
Tranche closed: A$650,000 raised
Use of proceeds: Support the ongoing Phase 1/2 clinical trial activities and general working capital
Jul 31, 2026US$456,561
Private placement of fully paid ordinary shares with 1-for-1 attaching options
Announced: A$4.4M · A$0.003 a share · Warrants at A$0.005 · PAC Partners Securities Pty Ltd +1
Dealers: PAC Partners Securities Pty Ltd (co-lead), Taylor Collison Limited (co-lead)
Buyers: US-based family office (US$2 M (~A$3 M) commitment)
Use of proceeds: CHM CDH17 CAR-T trial to end of Phase 1, CORE-NK clinical programs, working capital and offer costs
Dec 23, 2025US$2.94M
Convertible note
Announced: A$4M
Buyers: US institutional investor (A$4 M via Convertible Note)
Use of proceeds: Fund the CHM CDH17 CAR-T trial through Phase 1, including next patient cohort at an increased dose
Dec 23, 2025US$2.68M
Rights offering of new fully paid ordinary shares with attaching options
Closed: A$1M raised · 1 new attaching option for every New Share issued · PAC Partners +1
Dealers: PAC Partners (co-lead), Taylor Collison (co-lead)
Use of proceeds: Further runway to progress the company's programs
Apr 24, 2025US$639,490

Read by 6ix AI from the company's releases